JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Paulson, S. K.
Right arrow Articles by Karim, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Paulson, S. K.
Right arrow Articles by Karim, A.

Vol. 297, Issue 2, 638-645, May 2001

Pharmacokinetics of Celecoxib after Oral Administration in Dogs and Humans: Effect of Food and Site of Absorption

Susan K. Paulson , Margaret B. Vaughn, Susan M. Jessen, Yvette Lawal, Christopher J. Gresk, Bo Yan, Timothy J. Maziasz, Chyung S. Cook and Aziz Karim

Departments of Clinical Pharmacokinetics and Bioavailability (S.K.P., A.K.), Metabolism and Safety Evaluation (S.K.P., C.J.G., C.S.C.), Pharmaceutical Sciences (M.B.V.), Regulatory Affairs (S.M.J.), Information Resources (Y.L.), Statistics (B.Y.), and COX-2 Technology (T.J.M.), Pharmacia, Skokie, Illinois

Celecoxib pharmacokinetics was evaluated after single and multiple oral dosing; after dosing in a solution and as a solid; with and without food; and after administration into different sites of the GI tract using dog. After oral dosing in a solution, celecoxib was rapidly absorbed and reached maximum concentrations by 1 h; absorption was delayed another 1 to 2 h when administered as a solid. The absolute bioavailability of celecoxib was higher when given as a solution (64-88%) compared with capsule (22-40%). The absorption of celecoxib given in a capsule was delayed by food, although systemic exposure increased by 3- to 5-fold. The systemic availability of celecoxib given intragastrically in solution was similar to that obtained following direct instillation into the duodenum, jejunum, or colon through a chronic intestinal access port. Collectively, these data suggest that celecoxib is a highly permeable drug that can be absorbed throughout the GI tract and that dissolution may be a rate-limiting factor for absorption from solid dosage forms. Unlike dogs, celecoxib given to humans with a high fat meal exhibits only a slight increase in AUC0-infinity (11%) that is not clinically significant with regard to safety or efficacy. In humans, a lower dose and a longer GI residence time may promote the opportunity for absorption of a poorly soluble drug such as celecoxib that can be absorbed throughout the GI tract. This would minimize the effect of food on absorption; as such, patients with arthritis can be given celecoxib with or without food.


0022-3565/01/2972-0638$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Rheumatology (Oxford)Home page
S. C. Mastbergen, A. C. Marijnissen, M. E. Vianen, B. Zoer, P. M. van Roermund, J. W. Bijlsma, and F. P. Lafeber
Inhibition of COX-2 by celecoxib in the canine groove model of osteoarthritis
Rheumatology, April 1, 2006; 45(4): 405 - 413.
[Abstract] [Full Text] [PDF]


Home page
J Hum LactHome page
T. W. Hale, R. McDonald, and J. Boger
Transfer of Celecoxib into Human Milk
J Hum Lact, November 1, 2004; 20(4): 397 - 403.
[Abstract] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.